A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: Durability of benefit over a 1-year follow-up period

Journal of Clinical Psychiatry

Volumn 75, Issue 12, 2014, Pages 1394-1401

  Dunner, David L ^a,k   Aaronson, Scott T ^b   Sackeim, Harold A ^c   Janicak, Philip G ^d   Carpenter, Linda L ^e   Boyadjis, Terrence ^f   Brock, David G ^g   Bonneh Barkay, Dafna ^g   Cook, Ian A ^h   Lanocha, Karl ⁱ   Solvason, H Brent ^j   Demitrack, Mark A ^g  

^a Mercer Island   (United States)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e BUTLER HOSPITAL   (United States)

^f Private Practice Plymouth Meeting   (United States)

^g Neuronetics   (United States)

^h UCLA MEDICAL CENTER   (United States)

ⁱ Private Practice   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^k Center for Anxiety and Depression   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; OBSERVATIONAL STUDY; PATIENT HEALTH QUESTIONNAIRE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; TRANSCRANIAL MAGNETIC STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AGED; CLINICAL TRIAL; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FOLLOW UP; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; REMISSION; RETREATMENT; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; REMISSION INDUCTION; RETREATMENT; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923686304     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08977     Document Type: Article

References (38)

1. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858.
2. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
3. Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53(8):743-753.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006;163(11):1905-1917.
5. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study. Psychiatr Clin North Am. 2003;26(2):457-494, x.
6. Trivedi MH, Fava M, Wisniewski SR, et al; STAR∗D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al; STAR∗D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
9. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR∗D report. Am J Psychiatry. 2006;163(7):1161-1172.
10. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR∗D report. Am J Psychiatry. 2006;163(9):1531-1541, quiz 1666.
11. 3) augmentation following two failed medication treatments for depression: a STAR∗D report. Am J Psychiatry. 2006;163(9):1519-1530, quiz 1665.
12. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulat. 2010;3(4):187-199.
13. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008;69(2):222-232.
14. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507-516.
15. Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry. 2008;69(3):441-451.
16. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009;42(2):5-38.
17. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216.
18. Mantovani A, Pavlicova M, Avery D, et al. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. Depress Anxiety. 2012;29(10):883-890.
19. Dannon PN, Dolberg OT, Schreiber S, et al. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - preliminary report. Biol Psychiatry. 2002;51(8):687-690.
20. Dannon PN, Grunhaus L. Repetitive transcranial magnetic stimulation is effective following repeated courses in the treatment of major depressive disorder - a case report. Hum Psychopharmacol. 2003;18(4):313-315.
21. Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry. 2008;69(6):930-934.
22. Fitzgerald PB, Benitez J, de Castella AR, et al. Naturalistic study of the use of transcranial magnetic stimulation in the treatment of depressive relapse. Aust N Z J Psychiatry. 2006;40(9):764-768.
23. Benadhira R, Saba G, Samaan A, et al. Transcranial magnetic stimulation for refractory depression. Am J Psychiatry. 2005;162(1):193.
24. Cohen RB, Boggio PS, Fregni F. Risk factors for relapse after remission with repetitive transcranial magnetic stimulation for the treatment of depression. Depress Anxiety. 2009;26(7):682-688.
25. Dannon PN, Schreiber S, Dolberg OT, et al. Transcranial magnetic stimulation is effective in the treatment of relapse of depression. Int J Psychiatry Clin Pract. 2000;4(3):223-226.
26. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596.
27. Janicak PG, Dunner DL, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. CNS Spectr. 2013;18(6):322-332.
28. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Maryland: National Institute of Mental Health; 1976.
29. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67(9):1428-1434.
30. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
31. Katzelnick DJ, Duffy FF, Chung H, et al. Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv. 2011;62(8):929-935.
32. Inventory of Depressive Symptomatology-IDS/QIDS. 2013. www.ids-qids.org. Accessed August 15, 2014.
33. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):18-25.
34. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology. 2009;34(2):522-534.
35. McDonald WM, Durkalski V, Ball ER III, et al. Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety. 2011;28(11):973-980.
36. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67(5):688-695.
37. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38(12):2467-2474.
38. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143(1):18-23.